HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a $60 price target.
October 09, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $60.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Halozyme Therapeutics. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100